Loading
Galectins and Cancer Biology / Monoclonal and Polyclonal Antibodies Research · Journal article
Glycobiology · September 8, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review consolidating preclinical and mechanistic evidence on fungal lectins as potential immunomodulatory and diagnostic tools in cancer. The authors acknowledge that despite extensive in vitro work, clinical validation remains absent and translational pathways are underdeveloped. The work frames fungal lectins as hypothesis-generating candidates rather than established therapeutic or diagnostic agents.
Journal article.
Fungal lectins (AAL, LSL, MOA, AAG, RBL) demonstrate in vitro biological activity including cytokine regulation (TNF-α, IL-1β, IL-6, IL-10) and immune cell modulation Fungal lectins can recognize aberrant glycans such as TF and Tn antigens, suggesting diagnostic potential Clinical application is limited by insufficient in vivo validation and lack of translational research evidence
No clinical trial data, in vivo efficacy data, or safety pharmacology reported
Clinicians and researchers should view fungal lectins as emerging research candidates requiring rigorous in vivo evaluation and safety profiling before consideration for clinical use. Current evidence does not support clinical application in diagnosis, prognosis, or therapy.
A narrative review synthesizing mechanistic and in vitro evidence on fungal lectins as putative immunomodulators and diagnostic probes, with acknowledged absence of clinical validation and translational data.
Clinicians and researchers should view fungal lectins as emerging research candidates requiring rigorous in vivo evaluation and safety profiling before consideration for clinical use. Current evidence does not support clinical application in diagnosis, prognosis, or therapy.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Lectins are non-immunogenic, non-enzymatic proteins distributed across microbes, fungi, plants, invertebrates, and vertebrates. Their carbohydrate-binding specificity forms the basis of diverse biomedical applications, particularly in immunomodulation, prognosis, and diagnosis. Among these, fungal lectins have gained attention as promising biomolecules, although they remain less explored than their plant and animal counterparts. Several fungal lectins, including Aleuria aurantia lectin (AAL), Laetiporus sulphureus lectin (LSL), Marasmius oreades agglutinin (MOA), Agrocybe aegerita galectin (AAG), and Rhizoctonia bataticola lectin (RBL), demonstrate unique biological activities. They regulate immune responses by influencing cytokine expression (e.g. TNF-α, IL-1β, IL-6, IL-10), act on innate and adaptive immune cells, and initiate apoptosis or necrosis via intrinsic and extrinsic pathways. Their diagnostic potential lies in recognizing aberrant glycans such as TF and Tn antigens, while their prognostic relevance is associated with monitoring glycosylation changes during cancer progression. Collectively, fungal lectins represent versatile molecules capable of serving as both functional immunomodulators and sensitive glycan-based probes. Despite extensive in vitro studies, their clinical application remains limited by insufficient in vivo validation and translational research. Advancing fungal lectins into biomedical practice requires systematic evaluation of their safety, specificity, and therapeutic potential. This review consolidates current knowledge on fungal lectins in immunomodulation, prognosis, and diagnostics, and highlights their translational prospects. Future studies should prioritize in vivo evaluation, biosensor integration, and protein engineering approaches to fully exploit fungal lectins as next-generation tools in immunotherapy and precision medicine.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.